ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2020

Dec 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2020-12-07

Reporting Person: GIVEN DOUGLAS B (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-07	Common Stock	G	31000	$0.00	Disposed	123813	Direct
2020-12-07	Common Stock	G	15500	$0.00	Acquired	15500	Indirect
2020-12-07	Common Stock	G	15500	$0.00	Acquired	15500	Indirect
2020-12-17	Common Stock	S	9075	$79.30	Disposed	114738	Direct
2020-12-17	Common Stock	S	500	$79.59	Disposed	15000	Indirect

Footnotes

F1: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.

F2: Represents securities owned directly by Anne Given Trust ("AG Trust"). Mr. Given, as co-trustee of AG Trust, may be deemed to beneficially own the securities owned directly by AG Trust.

F3: Represents securities owned directly by Katherine Given Ligtenberg Trust ("KGL Trust"). Mr. Given, as co-trustee of KGL Trust, may be deemed to beneficially own the securities owned directly by KGL Trust.

F4: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.75 to $79.65, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F5: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.57 to $79.63, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.